Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice

American Journal of Pathology

Volumn 184, Issue 2, 2014, Pages 442-453

  Chang, Cherng Shyang ^a   Tsai, Pei Jane ^a   Sung, Junne Ming ^b   Chen, Ju Yi ^a,b   Ho, Li Chun ^a,c   Pandya, Kumar ^d   Maeda, Nobuyo ^d   Tsai, Yau Sheng ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c E DA HOSPITAL   (Taiwan)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; DIURETIC AGENT; FUROSEMIDE; GLUCOSE; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE; TRICHLORMETHIAZIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE; HEART; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; LIGAND BINDING; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PLASMA VOLUME; PRIORITY JOURNAL; THIAZOLIDINEDIONE INDUCED CARDIAC HYPERTROPHY; WILD TYPE;

ANIMALS; CARDIAC VOLUME; CARDIOMEGALY; DIURETICS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUROSEMIDE; GENE EXPRESSION REGULATION; GLUCOSE; INSULIN; LIPID METABOLISM; MICE; MICE, INBRED C57BL; PPAR GAMMA; SIGNAL TRANSDUCTION; SPIRONOLACTONE; THIAZOLIDINEDIONES; TRICHLORMETHIAZIDE;

EID: 84892147447     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.10.020     Document Type: Article

References (32)

1. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [Erratum appeared in N Engl J Med 2007, 357:100] N Engl J Med 356 2007 2457 2471
2. R.M. Lago, P.P. Singh, and R.W. Nesto Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials Lancet 370 2007 1129 1136
3. C.J. Rosen The rosiglitazone story-lessons from an FDA Advisory Committee meeting N Engl J Med 357 2007 844 846
4. S.M. Rangwala, and M.A. Lazar Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol Sci 25 2004 331 336
5. J.J. Lehman, and D.P. Kelly Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth Heart Fail Rev 7 2002 175 185
6. D.M. Kurtz, P. Rinaldo, W.J. Rhead, L. Tian, D.S. Millington, J. Vockley, D.A. Hamm, A.E. Brix, J.R. Lindsey, C.A. Pinkert, W.E. O'Brien, and P.A. Wood Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation Proc Natl Acad Sci USA 95 1998 15592 15597
7. N.H. Son, T.S. Park, H. Yamashita, M. Yokoyama, L.A. Huggins, K. Okajima, S. Homma, M.J. Szabolcs, L.S. Huang, and I.J. Goldberg Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice J Clin Invest 117 2007 2791 2801
8. J. Song, M.A. Knepper, X. Hu, J.G. Verbalis, and C.A. Ecelbarger Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats J Pharmacol Exp Ther 308 2004 426 433
9. Y. Guan, C. Hao, D.R. Cha, R. Rao, W. Lu, D.E. Kohan, M.A. Magnuson, R. Redha, Y. Zhang, and M.D. Breyer Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption Nat Med 11 2005 861 866
10. H. Zhang, A. Zhang, D.E. Kohan, R.D. Nelson, F.J. Gonzalez, and T. Yang Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention Proc Natl Acad Sci USA 102 2005 9406 9411
11. A.M. Katz Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure N Engl J Med 322 1990 100 110
12. J. Karalliedde, R. Buckingham, M. Starkie, D. Lorand, M. Stewart, G. Viberti Rosiglitazone Fluid Retention Study Group Effect of various diuretic treatments on rosiglitazone-induced fluid retention J Am Soc Nephrol 17 2006 3482 3490
13. A.J. Rennings, F.G. Russel, Y. Li, P.M. Deen, R. Masereeuw, C.J. Tack, and P. Smits Preserved response to diuretics in rosiglitazone-treated subjects with insulin resistance: a randomized double-blind placebo-controlled crossover study Clin Pharmacol Ther 89 2011 587 594
14. Y.S. Tsai, H.J. Kim, N. Takahashi, H.S. Kim, J.R. Hagaman, J.K. Kim, and N. Maeda Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma J Clin Invest 114 2004 240 249
15. A. Kis, C. Murdoch, M. Zhang, A. Siva, S. Rodriguez-Cuenca, S. Carobbio, A. Lukasik, M. Blount, S. O'Rahilly, S.L. Gray, A.M. Shah, and A. Vidal-Puig Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice Eur J Heart Fail 11 2009 533 541
16. M. Asakawa, H. Takano, T. Nagai, H. Uozumi, H. Hasegawa, N. Kubota, T. Saito, Y. Masuda, T. Kadowaki, and I. Komuro Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo Circulation 105 2002 1240 1246
17. P.H. Sugden, and A. Clerk "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium Circ Res 83 1998 345 352
18. P.P. Domingos, P.M. Fonseca, W. Nadruz Jr., and K.G. Franchini Load-induced focal adhesion kinase activation in the myocardium: role of stretch and contractile activity Am J Physiol Heart Circ Physiol 282 2002 H556 H564
19. D.N. Juurlink, T. Gomes, L.L. Lipscombe, P.C. Austin, J.E. Hux, and M.M. Mamdani Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 339 2009 b2942
20. E. Caglayan, B. Stauber, A.R. Collins, C.J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L.E. Peterson, R.S. Ross, R.K. Tangirala, and W.A. Hsueh Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis Diabetes 57 2008 2470 2479
21. S.Z. Duan, C.Y. Ivashchenko, M.W. Russell, D.S. Milstone, and R.M. Mortensen Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice Circ Res 97 2005 372 379
22. O.F. Bueno, and J.D. Molkentin Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death Circ Res 91 2002 776 781
23. C. Mihl, W.R. Dassen, and H. Kuipers Cardiac remodelling: concentric versus eccentric hypertrophy in strength and endurance athletes Neth Heart J 16 2008 129 133
24. A. Khoynezhad, Z. Jalali, and A.J. Tortolani Apoptosis: pathophysiology and therapeutic implications for the cardiac surgeon Ann Thorac Surg 78 2004 1109 1118
25. E. Borsting, V.P. Cheng, C.K. Glass, V. Vallon, and R. Cunard Peroxisome proliferator-activated receptor-gamma agonists repress epithelial sodium channel expression in the kidney Am J Physiol Renal Physiol 302 2012 F540 F551
26. C. Nofziger, and B.L. Blazer-Yost PPARgamma agonists, modulation of ion transporters, and fluid retention J Am Soc Nephrol 20 2009 2481 2483
27. V. Vallon, E. Hummler, T. Rieg, O. Pochynyuk, V. Bugaj, J. Schroth, G. Dechenes, B. Rossier, R. Cunard, and J. Stockand Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity J Am Soc Nephrol 20 2009 721 729
28. I. Goltsman, X. Wang, E.R. Lavallie, E.A. Diblasio-Smith, E. Ovcharenko, A. Hoffman, Z. Abassi, G.Z. Feuerstein, and J. Winaver Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure Circ Heart Fail 4 2011 345 354
29. L. Chen, B. Yang, J.A. McNulty, L.G. Clifton, J.G. Binz, A.M. Grimes, J.C. Strum, W.W. Harrington, Z. Chen, T.W. Balon, S.A. Stimpson, and K.K. Brown GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats J Pharmacol Exp Ther 312 2005 718 725
30. R.E. Booth, J.P. Johnson, and J.D. Stockand Aldosterone Adv Physiol Educ 26 2002 8 20
31. W.T. Festuccia, M. Laplante, S. Brûlé, V.P. Houde, A. Achouba, D. Lachance, M.L. Pedrosa, M.E. Silva, R. Guerra-Sá, J. Couet, M. Arsenault, A. Marette, and Y. Deshaies Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation J Mol Cell Cardiol 47 2009 85 95
32. N. Campbell, R. Brant, H. Stalts, J. Stone, and H. Mahallati Fluctuations in blood lipid levels during furosemide therapy: a randomized, double-blind, placebo-controlled crossover study Arch Intern Med 158 1998 1461 1463